(Q52552476)

3 May 2018

title

The effects of metformin on gut microbiota and the immune system as research frontiers. (English)

1 reference

3 May 2018

1 reference

Michael Pollak

1

1 reference

3 May 2018

publication date

2 August 2017

1 reference

3 May 2018

published in

Diabetologia

1 reference

3 May 2018

volume

60

1 reference

3 May 2018

issue

9

1 reference

3 May 2018

page(s)

1662-1667

1 reference

3 May 2018

https://scigraph.springernature.com/pub.10.1007/s00125-017-4352-x

exact match

0 references

cites work

Metformin: historical overview.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin: from mechanisms of action to therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Current understanding of metformin effect on the control of hyperglycemia in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Investigating metformin for cancer prevention and treatment: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Repurposing metformin: an old drug with new tricks in its binding pockets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin directly acts on mitochondria to alter cellular bioenergetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Transporters Involved in Metformin Pharmacokinetics and Treatment Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

The Role of the Immune System in Metabolic Health and Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

The Microbiome and Risk for Obesity and Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

An obesity-associated gut microbiome with increased capacity for energy harvest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Diet rapidly and reproducibly alters the human gut microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Gut metagenome in European women with normal, impaired and diabetic glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

A metagenome-wide association study of gut microbiota in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Antimicrobial activities of biguanides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin and the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Human gut microbes impact host serum metabolome and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Immune-mediated antitumor effect by type 2 diabetes drug, metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin as adjunct antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin as a Tool to Target Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Metformin improves healthspan and lifespan in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4352-X

Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin.

21 January 2018

1 reference

12 December 2020

The effects of metformin compared to the effects of phenformin on the lactate production and the metabolism of isolated parenchymal rat liver cell

1 reference

12 December 2020

Normalization of CD4+ T cell metabolism reverses lupus

1 reference

12 December 2020

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.

1 reference

12 December 2020

Metformin and pancreatic cancer: a clue requiring investigation

1 reference

12 December 2020

Metformin Suppresses Systemic Autoimmunity in Roquinsan/san Mice through Inhibiting B Cell Differentiation into Plasma Cells via Regulation of AMPK/mTOR/STAT3.

1 reference

12 December 2020

10.1007/S00125-017-4352-X

Identifiers

DOI

1 reference

3 May 2018

PubMed ID

28770326

1 reference

3 May 2018